Chemyx Fusion 200 Syringe Pump
Operated and passed basic function checks at intake, with no error codes. Light to moderate cosmetic wear from prior use. Not reconditioned.
Chemyx Inc
Details
-
CategoryPump
-
Dimension9.5in x 8.2in x 4.9in
-
Shipping TypeFedEx Ground
Description
The Chemyx Fusion 200-X Dual-Channel Syringe Pump is a precision laboratory syringe pump designed for controlled fluid handling and dispensing applications. Its 2-channel design allows two syringes to be used within a single system, making it suitable for research workflows requiring precise and controlled liquid delivery.
The Fusion 200-X can operate as a standalone syringe pump or be integrated into a larger laboratory setup, providing flexibility for research, biotechnology, chemistry, and other fluid-handling applications.
This unit has passed basic functional testing with no error codes observed. It shows light-to-moderate cosmetic wear consistent with previous use.
Key Features- Dual-channel syringe pump
- 2-channel design
- Precision fluid handling and dispensing
- Designed for controlled liquid delivery
- Standalone operation
- Can be integrated into larger laboratory systems
- Compact benchtop design
- Passed basic functional testing
- No error codes observed at intake
- Precision fluid dispensing
- Controlled reagent delivery
- Laboratory fluid handling
- Research and development
- Chemistry workflows
- Biotechnology research
- Experimental dosing and dispensing
Manufacturer: Chemyx Inc.
Model: Fusion 200-X
Product Type: Dual-Channel Syringe Pump
Channels: 2
Weight: 8.4 lb (3.81 kg)
Shipping Dimensions: 11.4 × 9.84 × 5.88 i
Product Enquiry
Have a question about this product? Send us your enquiry and our sales team will get back to you shortly.
Inform me when available
This item has sold. Leave your details and we will get in touch when a similar model becomes available.
Product Make Offer
Submit your best offer for this product. Our sales team will review your request and connect with you as soon as possible.
Comments 0
There are currently no public comments.